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llGlenn Biggs Institute of Alzheimer’s and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USAAbstract Introduction: Identifying circulating metabolites that are associated with cognition and dementia
may improve our understanding of the pathogenesis of dementia and provide crucial readouts for pre-
ventive and therapeutic interventions.
Methods: We studied 299 metabolites in relation to cognition (general cognitive ability) in two dis-
covery cohorts (N total5 5658).Metabolites significantly associatedwith cognition after adjusting for
multiple testing were replicated in four independent cohorts (N total 5 6652), and the associations
with dementia andAlzheimer’s disease (N5 25,872) and lifestyle factors (N5 5168) were examined.
Results: We discovered and replicated 15 metabolites associated with cognition including subfrac-
tions of high-density lipoprotein, docosahexaenoic acid, ornithine, glutamine, and glycoprotein ace-
tyls. These associations were independent of classical risk factors including high-density lipoprotein
cholesterol, low-density lipoprotein cholesterol, triglycerides, glucose, and apolipoprotein E (APOE)
genotypes. Six of the cognition-associated metabolites were related to the risk of dementia and life-
style factors.
Discussion: Circulating metabolites were consistently associated with cognition, dementia, and life-
style factors, opening new avenues for prevention of cognitive decline and dementia.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Cognitive function; General cognitive ability; Alzheimer’s disease; Dementia; Metabolites; Metabolomics; NMR;Lifestyle factors1. Introduction
Cognitive function is an important determinant of health
andwell-being and a key component of the dementia spectrum,
including Alzheimer’s disease (AD), the most common cause
of dementia [1]. Vascular dysfunction and metabolic dysregu-
lation contribute to impairment in cognitive performance [2].
Clinical and population-based studies suggest a relationship
of cognitive function with midlife hypertension, high blood
levels of total cholesterol (TC), low-density lipoprotein choles-
terol (LDL-C), triglycerides and glucose, and low levels of
high-density lipoprotein cholesterol (HDL-C) [3–5]. The
recent decrease in incidence of dementia in longitudinal
studies has been attributed to improved control of vascular
and metabolic factors [6–9]. These findings have fueled
speculation that discovery of other circulating metabolites
influencing cognition and future dementia may not only
improve our understanding of the determinants of cognition
but may also facilitate prevention through interventions on
lifestyle factors and dedicated medication [10]. Previous
studies have shown circulating metabolites in blood (e.g., lipo-
proteins, amino acids, fatty acids, and other small molecules)
to be associated with cognitive function and conversion fromnormal cognition to dementia or AD [11–17]. However,
these studies were relatively small and findings have not
been replicated [15,18], emphasizing the need for studies in
large well-characterized populations where findings are repli-
cated [10,19].
We performed a comprehensive metabolic analysis to
study the role of circulating metabolites in cognitive func-
tion. Discovery of novel measures associated with cognitive
function was performed in two large population-based
studies in the Netherlands—the Rotterdam Study (RS) and
the Erasmus Rucphen Family (ERF) study. We determined
whether the associations were independent of known
vascular and metabolic risk factors. Metabolites indepen-
dently associated with cognition were replicated in indepen-
dent cohort studies, and their relation to the risk of dementia
and AD was validated in eight cohort studies. Finally, we as-
sessed whether lifestyle factors, including dietary fish
intake, smoking, and physical activity, were associated
with the identified metabolites.
2. Methods
For a schematic overview of the analysis setup, see Fig. 1.
Fig. 1. Flowchart of analyses. Study names: ERF, RS, WHII, NTR, SHIP-Trend, FHS, VUmc ADC, Finrisk97, DILGOM, EGCUT, and AgeCoDe. Abbrevi-
ations: AgeCoDe, German Study on Ageing, Cognition, and Dementia; DHA, docosahexaenoic acid; EGCUT, Estonian Biobank; DILGOM, Dietary, Lifestyle,
and Genetic determinants of Obesity and Metabolic Syndrome; ERF, Erasmus Rucphen Family; FHS, Framingham Heart Study; Finrisk97, National FINRISK
Studies 1997; LDL, low-density lipoprotein; NTR, Netherlands Twin Register; RS, Rotterdam Study; SHIP-Trend, Study of Health in Pomerania–Trend; VUmc
ADC, VUmc Amsterdam Dementia Cohort; WHII, Whitehall II.
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cognitive function
Metabolomics profiling in multiple cohorts from the
Netherlands was done as part of the BioBanking for Medical
Research Infrastructure of the Netherlands (BBMRI) metab-
olomics consortium. These include the two discovery co-
horts (ERF and RS). A short description of the cohort
studies included in this article can be found in
Supplementary Table 1. ERF is a prospective family-based
study (ERF, N 5 2683) from the southwest of the
Netherlands, and the RS is a prospective population-based
cohort study that started in 1990 in Ommoord, a district of
Rotterdam. In this analysis, we used the fourth wave of the
baseline cohort (N 5 2975). Replication cohorts included
the Netherlands Twin Register (NTR, N 5 338; also part
of the BBMRI Metabolomics Consortium), the Whitehall
II (WHII, N 5 4612) study [20], the Framingham Heart
Study (FHS, N 5 2356), and the Study of Health in Pomer-
ania–Trend (N 5 944).2.2. Cohorts for extrapolation to dementia and AD
Dementia and AD was assessed in eight cohorts; the ERF
study, RS, a series of dementia patients and controls from the
VUmc Amsterdam Dementia Cohort metabolically charac-
terized as part of the BBMRI Metabolomics Consortium
(N 5 1303) [21], two cohorts used in the replication of
cognitive findings (WHII5 4,612 and FHS5 2356), the Na-
tional FINRISK Studies 1997 (Finrisk97; N 5 7517), Die-
tary, Lifestyle, and Genetic determinants of Obesity and
Metabolic Syndrome (DILGOM; N 5 4788), the Estonian
Biobank (EGCUT; N 5 2572), and the German Study on
Ageing, Cognition, and Dementia (AgeCoDe, N 5 310).2.3. Assessment of cognitive function and dementia
Participants underwent cognitive tests using a highly var-
iable battery of assessments, which varied across studies; de-
tails on the cognitive tests used can be found in
Supplementary Table 2. Cognitive function tests were
S.J. van der Lee et al. / Alzheimer’s & Dementia 14 (2018) 707-722710assessed at the same time point in all studies. To enable
meta-analyses of results from the heterogeneous set of tests
efficiently, we constructed a general cognitive ability scoreFig. 2. Associations of metabolites with general cognitive ability. The standardized
sex, body mass index, and lipid-lowering medication use are shown. The estimat
(yellow) analysis. Point estimates are shown as boxes with whiskers denoting
high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation.to capture information from a wide variety of cognitive tests
reliably into a single cognitive measure [22,23]. General
cognitive ability was calculated by principal componenteffect estimates on general cognitive ability of metabolites adjusted for age,
es are shown for the discovery (red), replication (green), and the combined
the 95% confidence interval of the effect estimates. Abbreviations: HDL,
Fig. 3. Association of metabolites with all-cause dementia and Alzheimer’s disease. The standardized OR of metabolites with all-cause dementia (red) and Alz-
heimer’s disease (blue) shown as point estimates with whiskers denoting the 95% confidence interval of the OR. Associations shown are adjusted for age (at entry),
sex, and if available body mass index and lipid-lowering medication. Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds ratio;
SD, standard deviation.
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component being the measure representing general
cognitive ability [22,24,25]. General cognitive ability can
be reliably estimated over the life course [26] and is verysimilar when derived from different cognitive test batteries
in the same individuals [22,23]. To ensure comparability
for the general cognitive ability in our study, only studies
that had cognitive tests covering at least three different
S.J. van der Lee et al. / Alzheimer’s & Dementia 14 (2018) 707-722712cognitive domains were included. The domains covered are
shown in Supplementary Table 3. General cognitive ability
accounted for between 35% and 58% of variance in cogni-
tive tests in various studies (Supplementary Table 3). Corre-
lations between the individual test measures and the derived
principal component (loadings) by study are shown in
Supplementary Table 3. In all studies, the general cognitive
ability had a high correlation with multiple single cognitive
measures, showing the factor was not driven by a single
measure.
Details on the ascertainment of dementia and AD for the
various cohorts can be found in Supplementary Table 2. The
diagnosis of dementia is based on continuous follow-up
health records in the ERF, WHII, EGCUT, Finrisk97, and
DILGOM. Studies that additionally used data on periodic
visits to a research center were the RS, FHS, and AgeCoDe.
The ascertainment of dementia and AD in the VUmc Am-
sterdam Dementia Cohort was done by clinical visits of par-
ticipants.
2.4. Assessment of genetic and environmental factors
In the two discovery cohorts, ERF and RS, apolipoprotein
E ε4 (APOE ε4) genotypes were determined by direct geno-
typing [27,28]. In both studies, lifestyle factors, including
smoking (current vs. past and never smokers), physical
activity (yes/no), and dietary fish (oil) intake [29] were as-
certained using questionnaires as described previously
[30,31]. Glucose, TC, HDL-C, LDL-C, and triglycerides
were measured in mainly fasting blood samples by standard
procedures [32,33]; further details are provided in
Supplementary Table 1. Multiple metabolites associated
with smoking and physical activity, and docosahexaenoic
acid (DHA) associated with fish intake (Fig. 4).Fig. 4. Association of metabolites with lifestyle factors. Lifestyle factors including
dietary fish (oil) intake. Metabolites are grouped based on their association with gen
effects estimates. Green shows the lifestyle factor associated with an increase in the
decrease in themetabolite concentration. Significance of the associations is shown *
index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; L, large par2.5. Assessment of blood metabolites
In the ERF and RS, the metabolic biomarkers were quan-
tified from fasted ethylenediaminetetraacetic acid (EDTA)
plasma samples using high-throughput proton nuclear mag-
netic resonance (NMR) metabolomics (Nightingale Ltd,
Helsinki, Finland). This method provides simultaneous
quantification of metabolites, that is, routine lipids, lipopro-
tein subclass profiling with lipid concentrations within 14
subclasses, fatty acid composition, and various low-
molecular weight metabolites including amino acids, ketone
bodies, and gluconeogenesis-related metabolites in molar
concentration units. Details of the experimentation and ap-
plications of this NMR metabolomics platform have been
described previously [34,35]. Metabolomics measurements
of the ERF study further included two NMR experiments
[35,36]. If a metabolite was measured in a study by
multiple experiments, the experiment measuring the
largest number of samples would be used. In total, 299
unique metabolite concentrations were measured in ERF;
and of these, 242 metabolites were also available in the
RS. The summary statistics of metabolomics
measurements in the discovery cohorts are shown in
Supplementary Table 4. The cohorts used for replication of
the cognitive findings and extrapolation to dementia used
NMR-based platforms or mass spectrometry techniques
(Supplementary Table 1). The Nightingale NMR platform
was also used in NTR, VUmc, EGCUT, WHII, Finrisk97,
and DILGOM. In NTR, additional NMR experiments
[35,36] were performed, and again the experiment with the
largest number of observations was used. Measurements of
cognitive function and blood drawn for metabolite
measurements were concurrent in all metabolite
measurements from our discovery and 73.6% of thesmoking (current vs. past and never smokers), physical activity (yes/no), and
eral cognitive ability and subfraction of HDL. Colors represent standardized
metabolite concentration, and red shows the lifestyle factor associated with a
P, .05, **P, .001, and ***P, 1! 1025. Abbreviations: BMI, bodymass
ticles; M, medium particles; S, small particles.
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Samples used in replication and extrapolation were collected
after overnight fasting; except for the samples at the VUmc
Alzheimer Center and Finrisk97, which were nonfasting or
“semifasting” (participants were instructed to fast for 4 hours
before the scheduled examination). The summary statistics
of metabolomics measurements in the cohorts used for the
replication of the cognitive findings and the cohorts used
for extrapolation to dementia are shown in Supplementary
Table 5.2.6. Statistical analyses
Histograms of classical blood measurements and metab-
olites in the discovery cohorts were visually inspected for
non-normality, if necessary natural logarithmic or rank-
transformations were applied (Supplementary Table 4).
Individuals who had suffered from a stroke or who were
diagnosed with dementia at the time of cognitive assessment
were excluded. Linear regression analyses were used to
assess the relation of standardized measures of TC, HDL-C,
LDL-C, triglycerides, and glucose with general cognitive
ability, adjusting for age, sex, lipid-lowering medication
(yes/no), and body mass index (BMI) as covariates. The ef-
fect of APOE ε4 on general cognitive ability was assessed
using an additivemodel. The association of 299 standardized
metabolites with general cognitive ability was assessed us-
ing linear regression with age, sex, BMI, and lipid-
lowering medication as covariates (model 1). To test if the
identified associations were independent of the classically
measured and frequently studied circulating markers, we
ran a second model (model 2) where we additionally
included TC, HDL-C, LDL-C, triglycerides, and glucose
as covariates to model. Finally, we tested if the identified
metabolites–general cognitive ability association were
confounded by APOE ε4 (model 3).
Because metabolites are highly correlated, we used the
method of Li and Ji [37] to correct for multiple testing.
The method calculates the number of independent tests in
correlated measures. In this study, testing 299 metabolites
corresponded to 87 independent tests (P for
significance5 0.05/875 5.7! 1024). To assess the relation
of metabolites found to be associated with cognitive function
to incident dementia and AD, we used Cox proportional haz-
ard models when data came from prospective studies. Again,
we standardized the metabolite levels and adjusted for age
(at entry), sex, BMI, and lipid-lowering medication. For
VUmc Alzheimer Center, we used logistic regression
adjusted for age and sex. The relations with incident demen-
tia and AD were evaluated in a second model additionally
adjusting for APOE ε4 genotypes.
In the discovery cohorts, we used linear regression anal-
ysis to study associations of lifestyle factors (smoking, phys-
ical activity, and fish [oil] consumption) with metabolites
and cognitive function, adjusting for age, sex, BMI, and
lipid-lowering medication. All analyses were performed inR (version 3.2.1, 2015-06-18). Summary statistics by cohort
were combined with inverse variance-weighted fixed-effects
meta-analysis using the “rmeta” package (version 2.16). The
association magnitudes are reported in units of standard de-
viation (SD) or odds ratio (OR) change per 1-SD increase in
each metabolite [38,39] easing comparison of effects.3. Results
Clinical characteristics of all cohorts analyzed in this
study are provided in Table 1. Results of the association of
general cognitive ability with baseline clinical characteris-
tics in the discovery cohorts are shown in Table 2. As ex-
pected, general cognitive ability was higher in participants
with higher education and was inversely associated with
increasing age and the presence of APOE ε4 allele. Increased
HDL-C was associated with higher general cognitive ability
(0.034 SD higher general cognitive ability per 1 SD higher
HDL-C concentration; P 5 6.4 ! 1023), whereas fasting
glucose levels were associated with lower cognitive ability
(0.039 SD; P 5 2.2 ! 1023).3.1. The metabolic profile of general cognitive ability
We identified 18 metabolites that were significantly asso-
ciated (P , 5.9 ! 1024 [model 1]) with general cognitive
ability (listed as top 18 associations in Supplementary
Table 6). Association results can be accessed through http://
bbmri.researchlumc.nl/atlas. Of the 18 metabolites, XXL-
LDL-triglycerides were not measured in the replication co-
horts; therefore, 17 metabolites were tested for replication
in independent cohorts (Supplementary Table 7 [model 1],
Nmax 5 6652). Of these 17, we found 15 to be associated
with general cognitive ability in the replication cohorts
(Preplication , .05, Table 3). Thirteen metabolites surpassed
the more stringent Bonferroni corrected threshold for signifi-
cance in the replication (Preplication , 2.9 ! 10
23).
Combining discovery and replication data (Table 3), 12 me-
tabolites were associated with higher general cognitive ability
and threewere associatedwith lower general cognitive ability.
The metabolites associated with increased higher cognitive
ability include 11 HDL subfractions, the most significant be-
ing free cholesterol in HDL (0.078 SD;P5 2.3! 10215) and
docosahexaenoic acid (DHA or 22:6[n-3]) an omega-3-fatty
acid (0.060 SD; P 5 9.8 ! 10211). The three metabolites
that were associated with lower general cognitive ability
include glycoprotein acetyls (20.075 SD; P 5 5.4 !
10213), glutamine (20.042 SD; P 5 2.8 ! 1027), and orni-
thine (20.057 SD; P 5 8.5 ! 1027). Of the 15 metabolites
significantly associated with general cognition, only two me-
tabolites, HDL-C esters (Pmodel25 9.9! 10
23) and medium
HDLTC (Pmodel25 7.9! 10
23), lost their significance in the
combined analysis when additionally adjusting for glucose,
TC, HDL-C, LDL-C, and triglycerides (Supplementary
Table 7 [model 2]). However, adjustment did not result in a
major change in effect estimates for these two metabolites,
Table 1
Baseline characteristics of all studied 11 cohorts
Variables ERF RS WHII NTR SHIP-Trend FHS VUmc ADC Finrisk97 DILGOM EGCUT AgeCoDe
Number of samples in cognitive
analysis
2683 2505 4235 338 944 1508 - - - - -
Age (years) 48.9 6 14.2 74.2 6 6.2 55.8 6 6.0 40.7 6 12.4 50.1 6 13.6 55.7 6 9.8 64.1 6 9.0 48.8 6 13.5 52.3 6 13.5 59.1 6 12.4 84.1 6 3.1
N-Women (%) 56.1 58.2 26.2 62.4 56.4 52.5 45.1 54.7 55.8 58.9 69.4
Education (1–4 scale) 2.1 6 0.9 2.4 6 0.9 2.0 6 0.8 3.2 6 0.8 2.4 6 0.9 2.3 6 0.6 * 5.0 6 1.0y 2.0 6 0.8* 2.1 6 0.8* 3.0 6 0.8 -
Body mass index (kg/m2) 27 6 4.7 27.4 6 4.1 25.9 6 3.8 24.7 6 4 27.4 6 4.6 27.5 6 4.9 25.3 6 3.8 26.7 6 4.6 27.2 6 4.9 28 6 5.1 25.6 6 3.7
Lipid-lowering medication (%) 12.7 22.8 3.0 7.0 7.4 7.6 19.5 3.49 15.6 24 21.6
APOE ε4 carriers (%) 37.7 27.6 27.7 26.6 22.5 22.5 51.7 35.1 24 23.6 20.3
Diastolic blood pressure (mm Hg) 80 6 10 79 6 11 77 6 10.3 76 6 9.8 76.7 6 10 75 6 10 86 6 11 83 6 11.24 79 6 11 82 6 10 78 6 8.0
Systolic blood pressure (mm Hg) 140 6 20 152 6 21 122 6 15 124 6 12 124 6 16 126 6 18 141 6 19 136 6 20 137 6 20 134 6 17 136 6 15
Established blood measures
TC (mmol/L) 5.6 6 1.1 5.6 6 1.0 5.9 6 1.0 5.1 6 1.1 5.5 6 1.1 5.3 6 1.0 4.9 6 1.0 5.5 6 1.1 5.3 6 1.0 5.8 6 1.1 5.8 6 1.1
LDL-cholesterol (mmol/L) 3.7 6 1.0 3.5 6 0.9z 3.8 6 0.9 3.1 6 1.0 3.4 6 0.9 3.3 6 0.9 1.7 6 0.5 3.5 1 0.9z 3.2 6 0.8z 2.2 6 0.7 3.5 6 1.0
HDL-cholesterol (mmol/L) 1.3 6 0.4 1.5 6 0.4 1.5 6 0.4 1.4 6 0.3 1.5 6 0.4 1.3 6 0.4 1.5 6 0.4 1.39 6 0.4 1.44 6 0.4 1.7 6 0.4 1.6 6 0.4
Triglycerides (mmol/L) 1.3 6 0.8 1.49 6 0.7 1.3 6 0.8 1.4 6 0.7 1.4 6 0.9 1.7 6 1.4 1.4 6 0.7 1.51 6 1.1 1.43 6 0.9 1.8 6 1.1 1.4 6 0.6
Glucose (mmol/L) 4.7 6 1.1 5.9 6 1.5 5.2 6 1 5.4 6 0.7 5.4 6 0.6 5.6 6 1.5 5.7 6 1.7 4.61 6 1.1 4.12 6 0.8 4.6 6 1.7 -
Dementia analysis
Number of samples 1532 2010 4612 - - 2356 1303 7517 4788 2572 310
Follow-up time (years) 11.3 6 1.7 7.6 6 3.6 16.7 6 1.6 - - 15.7 6 5 - 9.67 6 1.35 7.68 6 0.9 7.03 6 2.22 4.5 6 1.8
Maximum follow-up 13.6 11.7 17.9 - - 22.6 - 10 7.9 12.9 6.4
Number of AD cases 28 346 35 - - 81 665 100 75 - 75
Number of dementia cases 39 506 114 - - 110 917 141 81 41 82
Abbreviations: AD, Alzheimer’s disease; AgeCoDe, German Study on Ageing, Cognition, and Dementia; APOE, apolipoprotein E; DILGOM, Dietary, Lifestyle, and Genetic determinants of Obesity and
Metabolic Syndrome; EGCUT, Estonian Biobank; ERF, Erasmus Rucphen Family; FHS, FraminghamHeart Study; Finrisk97, The National FINRISK Studies 1997; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; NTR, Netherlands Twin Register; RS, Rotterdam Study; SHIP-Trend, Study of Health in Pomerania–Trend; TC, total cholesterol; VUmc ADC, VUmc Amsterdam
Dementia Cohort; WHII, Whitehall II.
NOTE. For VUmc ADC, Finnrisk97, DILGOM, EGCUT, and AgeCoDE the descriptive statistics are calculated based on the samples in the dementia analysis.
*Education in 1–3 scale.
yEducation in 1–7 scale.







































Association of characteristics with general cognitive ability in discovery cohorts
Phenotype
ERF study Rotterdam Study Meta-analysis
Effect (6SE) P value N Effect (6SE) P value N Effect (6SE) P value N
Age 20.042 (60.001) 2.1 ! 102280 2699 20.078 (60.003) 1.1 ! 102154 2483 20.046 (60.001) ,1 ! 102500 5182
Sex (male vs. female) 20.020 (60.029) 0.49 2699 0.142 (60.035) 3.8 ! 1025 2483 0.048 (60.022) 3.1 ! 1022 5182
BMI 0.005 (60.003) 0.15 2694 20.015 (60.004) 3.1 ! 1024 2483 20.003 (60.003) 0.30 5177
Education 0.410 (60.017) 1.4 ! 102117 2699 0.277 (60.020) 1.5 ! 10241 2483 0.355 (60.013) ,1 ! 102500 5182
APOE ε4 20.046 (60.028) 0.09 2342 20.157 (60.035) 9.0 ! 1026 2378 20.088 (60.022) 5.2 ! 1025 4720
Lipid-lowering medication 20.131 (60.047) 5.8 ! 1023 2690 0.013 (60.042) 0.76 2397 20.050 (60.031) 0.11 5087
Classical blood measures
TC 20.011 (60.016) 0.50 2635 0.022 (60.019) 0.24 2481 0.003 (60.012) 0.8 5116
LDL-C* 20.026 (60.016) 0.10 2621 0.016 (60.019) 0.41 2265 20.009 (60.012) 0.45 4886
HDL-C 0.037 (60.016) 2.3 ! 1022 2635 0.029 (60.019) 0.13 2401 0.034 (60.012) 6.4 ! 1023 5036
Triglycerides 20.014 (60.016) 0.36 2637 20.017 (60.018) 0.35 2345 20.015 (60.012) 0.19 4982
Glucose 20.047 (60.017) 6.2 ! 1023 2623 20.029 (60.019) 0.12 2401 20.039 (60.013) 2.2 ! 1023 5024
Abbreviations: APOE, apolipoprotein E; BMI, body mass index; ERF, Erasmus Rucphen Family; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; SD, standard deviation; SE, standard error; TC, total cholesterol.
NOTE. Multivariate analysis of general cognitive ability with age was adjusted for sex and with sex was adjusted for age. Association of general cognitive
ability with BMI, educational level, APOE, and lipid-lowering medication use adjusted for age and sex. Associations of general cognitive ability with blood
measures (TC, LDL-C, HDL-C, triglycerides, and glucose) were adjusted for age, sex, and lipid-lowering medication use. The association magnitudes are re-
ported in units of SD change (6SE) per 1-SD increase in each metabolite [38,39].
*LDL-C in the Rotterdam Study was estimated using the Friedewald estimation.
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[model 2]). Adjusting for APOE ε4 did not change any of
the 15 associations (Supplementary Table 7 [model 3] and
Supplementary Fig. 1 [model 3]). In Box 1, we summarize
the functions of the metabolites we found associated with
general cognitive ability.3.2. Association of the metabolic profile with dementia
and AD
Next, we examined whether the 15metabolites associated
with general cognitive abilitywere associated with dementia.
We compared (maximum) 1990 dementia patients, of whom
1356 were AD cases, with 23,882 controls. Six metabolites
were associated with dementia, and three of these were also
associated with AD (P, .05; Table 4, for all association re-
sults, see Supplementary Table 8 and Fig. 3). Free cholesterol
in small HDL associated most significantly with a lower risk
of dementia (OR5 0.85 per 1-SD increase inmetabolite con-
centration; 95% CI 5 0.80–0.91; P 5 6.3 ! 1027) and AD
(OR5 0.87; 95% CI5 0.81–0.94; P5 2.3! 1024). Other
metabolites associated with a lower dementia risk were DHA
(OR 5 0.92; 95% CI 5 0.86–0.97; P 5 3.4 ! 1023; AD,
P5 1.5! 1023) and subfractions of medium size HDL par-
ticles (phospholipids P 5 2.5 ! 1023, TC P 5 .025, and
cholesterol esters P 5 .025). Higher glutamine levels were
associated with an increased risk of dementia (OR 5 1.08;
95% CI 5 1.02–1.15; P 5 .011) and AD (OR 5 1.11; 95%
CI 5 1.04–1.20; P 5 3.0 ! 1023). The association of free
cholesterol in small HDL and DHA surpassed the more strin-
gent Bonferroni corrected threshold for significance
(P, 1.5! 1023). After additionally adjusting for the num-
ber of APOE ε4 alleles, the associations of dementia and ADwith subfractions of medium size HDL particles were no
longer significant (P . .05; Supplementary Table 8 and
Supplementary Fig. 2).
3.3. Association of the metabolic profile with lifestyle
factors
The analyses of the association of lifestyle factors with
metabolites and general cognitive ability are shown in
Supplementary Table 9 and summarized in Fig. 4. Fish
(oil) intake was strongly associated with DHA blood con-
centrations (P 5 9.9 ! 10253). Physical activity was asso-
ciated with increased (P , .05) levels of metabolites that
were associated with higher cognitive function (medium
and large HDL subfractions) and decreased levels of metab-
olites that were associated with lower cognitive function
(glycoprotein acetyls, ornithine, and glutamine). Smokers
had decreased concentrations of all HDL subfractions asso-
ciated with higher cognitive function and increased concen-
trations of metabolites associated with decreased cognitive
function (Fig. 4).4. Discussion
In this study, we discovered and replicated 15 metabolites
associated with general cognitive ability. This metabolic
profile includes subfractions of HDL, DHA, ornithine, gluta-
mine, and glycoprotein acetyls. We show that metabolites in
the profile are independent of classical cardiometabolic
blood correlates of cognitive function. Of the 15 replicated
metabolites, six were associated with dementia and three
of these also with AD. Furthermore, we show that lifestyle
factors, such as diet, smoking, and physical activity, have
strong effects on metabolites in the profile.
Table 3
Association of metabolites with general cognitive ability
Metabolite
Discovery Replication Meta-analysis
I2 P-I2Effect (6SE) P value N Effect (6SE) P value N Effect (6SE) P value N
HDL-free cholesterol 0.067 (60.013) 1.5 ! 1027 4791 0.094 (60.015) 1.2 ! 1029 4542 0.078 (60.010) 2.3 ! 10215 9333 63 6.7 ! 1022
L-HDL-free cholesterol 0.059 (60.013) 3.4 ! 1026 4793 0.106 (60.016) 6.2 ! 10211 4542 0.077 (60.010) 1.5 ! 10214 9335 80 7.3 ! 1023
L-HDL-total cholesterol 0.052 (60.013) 5.0 ! 1025 4792 0.108 (60.016) 3.5 ! 10211 4542 0.073 (60.010) 3.5 ! 10213 9334 79 8.2 ! 1023
Glycoprotein acetyls 20.064 (60.014) 4.5 ! 1026 3778 20.087 (60.015) 1.4 ! 1028 4542 20.075 (60.010) 5.4 ! 10213 8320 0 0.60
L-HDL-cholesterol esters 0.048 (60.013) 1.5 ! 1024 4792 0.108 (60.016) 3.4 ! 10211 4542 0.071 (60.010) 1.6 ! 10212 9334 80 7.6 ! 1023
L-HDL-phospholipids 0.045 (60.013) 4.2 ! 1024 4791 0.100 (60.016) 3.3 ! 10210 4542 0.067 (60.010) 2.2 ! 10211 9333 78 9.7 ! 1023
HDL-phospholipids 0.050 (60.013) 9.5 ! 1025 4790 0.089 (60.015) 9.8 ! 1029 4542 0.066 (60.010) 2.5 ! 10211 9332 68 4.3 ! 1022
HDL-total cholesterol 0.048 (60.013) 2.1 ! 1024 4796 0.088 (60.016) 1.5 ! 1028 4542 0.064 (60.010) 9.8 ! 10211 9338 66 5.4 ! 1022
22:6, docosahexaenoic acid 0.047 (60.014) 5.4 ! 1024 3772 0.070 (60.012) 2.1 ! 1028 5480 0.060 (60.009) 9.8 ! 10211 9252 67 4.6 ! 1022
M-HDL-phospholipids 0.063 (60.013) 8.2 ! 1027 4799 0.057 (60.014) 7.2 ! 1025 4542 0.060 (60.010) 2.5 ! 10210 9341 0 0.48
M-HDL-total cholesterol 0.046 (60.013) 3.0 ! 1024 4799 0.054 (60.014) 1.5 ! 1024 4542 0.050 (60.010) 1.8 ! 1027 9341 0 0.62
M-HDL-cholesterol esters 0.046 (60.013) 2.5 ! 1024 4799 0.052 (60.014) 2.6 ! 1024 4542 0.049 (60.009) 2.4 ! 1027 9341 0 0.63
Glutamine 20.052 (60.012) 2.5 ! 1025 4715 20.034 (60.011) 1.8 ! 1023 6652 20.042 (60.008) 2.8 ! 1027 11,367 74 9.8 ! 1023
S-HDL-free cholesterol 0.059 (60.012) 8.4 ! 1027 4796 0.029 (60.014) 4.0 ! 1022 4542 0.047 (60.009) 3.5 ! 1027 9338 0 0.55
Ornithine 20.083 (60.018) 4.5 ! 1026 2228 20.039 (60.015) 1.0 ! 1022 2750 20.057 (60.012) 8.5 ! 1027 4978 43 0.18
L-LDL-triglycerides 20.055 (60.012) 3.7 ! 1026 4797 0.018 (60.015) 2.3 ! 1021 4542 20.027 (60.009) 4.2 ! 1023 9339 90 3.6 ! 1025
M-LDL-triglycerides 20.042 (60.012) 5.1 ! 1024 4800 0.019 (60.015) 1.9 ! 1021 4542 20.018 (60.009) 6.3 ! 1022 9342 85 1.3 ! 1023
Abbreviations: APOE, apolipoprotein E; HDL, high-density lipoprotein; I2, measure for heterogeneity in the meta-analysis in percent; LDL, low-density lipoprotein; L, large particles; M, medium particles;
P-I2, P value for heterogeneity; S, small particles; SD, standard deviation; SE, standard error.
NOTE. Glycoprotein acetyls are mainly a-1-acid glycoprotein. The association magnitudes are reported in units of SD change (6SE) per 1-SD increase in each metabolite [38,39]. Shown associations of the







































Description of pathways of metabolites in the context of cognitive function
High-density lipoprotein subfractions
The specific lipoprotein subfractions could point to the specific functions of lipoprotein subfractions. High-density lipo-
protein (HDL) fractions are well known to be individually tasked for different functions across lipid metabolism, inflamma-
tion, anti-oxidation, and host defense [40,41]. In addition, specific protein pairs on specific HDL subspecies exist that
maintain stable compositions [42]. Previous research reported links between HDL cholesterol profiles and changes in
vascular health with plaque accumulation in arteries of the brain, damage to the blood brain barrier [43], and occurrence of
thrombosis. All are possibly leading to progressive vascular brain damage resulting in loss of white matter microstructural
organization.
Docosahexaenoic acid
Docosahexaenoic acid (DHA) levels in blood are highly associated with omega-3-fatty acid intake through diet [39], and
it cannot be de novo synthesized in the brain and is therefore actively transported over the blood-brain barrier through the
Mfsd2a [44,45]. DHA is essential for normal brain development in early life and is frequently associated with cognition [46].
High intake might also be beneficial in late life as DHA and fish oil intake associated with less Alzheimer’s disease pa-
thology [47]. The evidence of the attributed beneficial effects of DHA on the brain in literature is inconsistent [48].
Glutamine
In the brain, glutamine is not only used for energy production and protein synthesis, as in other cells, but is also an essen-
tial precursor for biosynthesis of amino acid neurotransmitters. It is involved in the glutamine-glutamate/GABA cycle, a
well-studied concept in excitatory signaling in the brain [49]. The cycle involves transfer of glutamine from astrocytes to
neurons and neurotransmitter glutamate or GABA from neurons to astrocytes. The leading opinion in the field is that in the
brain an excess of glutamate, excitotoxicity, is seen as detrimental and glutamine in the brain as beneficial [50].
Glycoprotein acetyls
The measured glycoprotein acetyls is mainly a-1-acid glycoprotein (AGP) [34], also called orosomucoid, which is an
acute phase plasma a-globulin glycoprotein. The protein is widely studied and has previously been found to predict 10-year
mortality [51]. Increased plasma levels of glycoprotein acetyls as reaction to various diseases (cancer and inflammatory
diseases) or following trauma (surgery) might explain the association with increased mortality and could partially explain
the association with general cognitive ability as chronic diseases decrease cognitive abilities. Another function of AGP is to
carry mainly neutrally charged medications in blood, for example, antidepressants [52]. The plasma concentration of AGP is
relatively low, and there is only one drug-binding site in each AGP molecule [53], leading to lower antidepressant response
in higher AGP concentrations [54].
Ornithine
Ornithine as a non–proteinogenic amino acid is an important intermediate product in arginine degradation and urea cycle.
Hyperornithinemia is also the biochemical hallmark of an inherited metabolic disease, hyperornithinemia-hyperammone-
mia-homocitrullinuria syndrome [55]. This disease is clinically characterized by mental retardation whose pathogenesis
is still poorly known.
S.J. van der Lee et al. / Alzheimer’s & Dementia 14 (2018) 707-722 717The most interesting metabolite in the profile is DHA, a
long-chain omega-3 polyunsaturated fatty acid. As the
largest cross-sectional study to date studying DHA in rela-Table 4
Metabolite concentrations associated with dementia and AD
Metabolite
AD
OR P value N cases
S-HDL-free cholesterol 0.87 [0.81–0.81] 2.3 ! 1024 1276
M-HDL-phospholipids 0.93 [0.86–0.86] 4.7 ! 1022 1276
22:6, docosahexaenoic acid 0.89 [0.83–0.83] 1.5 ! 1023 1334
Glutamine 1.11 [1.04–1.04] 3.1 ! 1023 1356
M-HDL-cholesterol esters 0.97 [0.89–0.89] 0.38 1276
M-HDL-total cholesterol 0.97 [0.89–0.89] 0.40 1276
Abbreviations: AD, Alzheimer’s disease; BMI, body mass index; HDL, high-d
decrease in AD or dementia risk per 1-SD increase of metabolite concentration.
NOTE. Sorted by the P values for dementia. Combined results from Cox propo
Associations shown are adjusted for age (at entry), sex, and if available BMI andtion to cognitive function, the present study showed compel-
ling evidence that DHA levels in blood were associated with
higher cognitive function (P5 9.8! 10211). This finding isDementia
N total OR P value N cases N total
22,880 0.85 [0.80–0.80] 4.1 ! 1027 1881 25,868
22,884 0.90 [0.85–0.85] 1.8 ! 1023 1881 25,872
22,466 0.91 [0.86–0.86] 1.9 ! 1023 1938 25,417
25,181 1.08 [1.02–1.02] 1.3 ! 1022 1990 25,640
22,884 0.92 [0.86–0.86] 1.6 ! 1022 1881 25,872
22,884 0.92 [0.86–0.86] 1.6 ! 1022 1881 25,872
ensity lipoprotein; L, large; M, medium; OR, odds ratio for the increase or
rtional hazard models and logistic regression models are presented as OR.
lipid-lowering medication. N total is the sum of cases and controls.
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holm et al. [46], suggesting a relation between nutritive
DHA intake, or fish (oil) intake as its proxy, and better cogni-
tion. Blood levels of DHA are raised by eating fat fish, as
also in our study. DHA from diet is most likely actively
transported over the blood-brain barrier by Mfsd2a
[44,56], where it is abundant in gray matter [57] and found
in lower concentrations in brains of individuals with AD
[58]. We showed for the first time that DHA in blood was
associated with a lower risk of AD and dementia, using
blood measures of DHA in up to 22,887 individuals. Taken
together, our study implies that high levels of DHA could
be beneficial for cognitive function, potentially also
reducing the risk of dementia and AD.
Beyond the association of high HDL-C with better cogni-
tive function [3–5], the present study points toward a role of
cholesterol, free cholesterols, and phospholipids in small,
medium, and large subclasses of HDL. However, current
knowledge of the functions of HDL subclasses is limited;
thus, we can only speculate on the pathways through
which the metabolites that we observed exert their effect
on cognitive function [59]. Phospholipids could have a direct
effect as they are the main constituents of neuronal mem-
brane structures, such as presynaptic and postsynaptic mem-
branes, and neuronal membrane degeneration has been
linked to synapse loss in AD [60]. Possibly, circulating phos-
pholipids and free cholesterols in HDL form a buffer to
repair damaged membranes. This is supported by the obser-
vation that both AD patients and patients with mild cognitive
impairment have lower circulating levels of nutrients
involved in phospholipid synthesis in blood and cerebrospi-
nal fluid [61]. Alternatively, the free cholesterols in the phos-
pholipid layer of HDL tag the presence of other important
proteins that are transported to or are disposed from the
brain. HDL contains up to 95 proteins and lipids that may
segregate into distinct subclasses of HDL and lead to
subclass-specific effects [42,62]. Regions in membranes of
both neurons and astrocytes [63], where HDL-related free
cholesterols, sphingomyelins, and free fatty acids (such as
DHA) concentrate, are called lipid rafts. Changes in lipid
raft composition may be an early marker of neurodegenera-
tive diseases [64]. A hypothesis that requires further study is
that increased free cholesterols in (small) HDL and DHA in
blood affects lipid raft quantity, composition, or cell-
signaling leading to beneficial effects on the brain.
In our study, levels of glycoprotein acetyls, mainly a-1-
acid glycoprotein (also known as orosomucoid, an acute
phase protein), were associated with lower cognitive func-
tion, smoking, and physical activity. Glycoprotein acetyl
concentration has been shown to be a strong predictor of
10-year mortality [51,65]. A major genetic determinant of
glycoprotein acetyl levels in blood is located close to the
gene coding for haptoglobin (HP) [35]. This protein may
link our findings of HDL subfractions to that of glycoprotein
acetyls, as the HP protein has been found in specific HDL
subfractions [62]. Furthermore, the HP gene was previouslyassociated with the risk of cognitive impairment in type 2
diabetes with poor glycemic control [66].
Two nonessential amino acids that were associated with
lower cognitive function were ornithine, which is part of
the urea cycle, and glutamine. Ornithine accumulation
causes hyperornithinemia-hyperammonemia-homocitrullinuria
syndrome [55], a disease with a currently poorly known patho-
genesis, which is clinically characterized by mental retardation
[67]. Glutamine and its closely related neurotransmitter gluta-
mate have been found to be differentially expressed in brains
of AD patients [49]. In the brain, glutamate is considered harm-
ful [49], and our population-based studies suggest that in the cir-
culation, glutamine is associated with lower cognition. Both
ornithine and glutamine are interesting targets for further studies.
A major strength of the present study is the large sample
size, both in the discovery and replication. To our knowledge,
this is the largest study exploring the association of a large
array of blood-basedmetabolites with general cognitive abil-
ity to date. Other strengths are the similar methods across
studies used to determine metabolites and the use of general
cognitive ability to harmonize the studied cognitive outcome
[23]. We chose to analyze the associations of metabolites
with cognitive ability in the largest sample size available, ac-
cepting that subtle differences in cognitive testing, metabo-
lite measuring, study design, and populations would
introduce heterogeneity of effects and then followed by a
replication in independent samples; this approach ismodeled
to the standard approach followed in genome-wide associa-
tion studies [68]. A potential limitation of our cross-
sectional study of cognition is that we cannot determine cau-
sality of the associationwith circulatingmetabolites. Howev-
er, in our extrapolation to dementia and AD, we mostly
studied incident cases with metabolites measured before
the disease onset, suggesting that at least the six dementia-
associated metabolites are most likely in a causal pathway.
We note that the associations of the HDL subfractions asso-
ciated with dementia were attenuated by the APOE ε4 geno-
type, suggesting they could be in the causal pathway of
APOE ε4 to dementia or the associations found are pleio-
tropic effects ofAPOE ε4. Last but not least, we did not adjust
for education because cognition and education are highly
correlated [69] if measured at the same time. In fact, there
is still debate on whether education determines cognitive
ability [26,70] or vice versa [71,72]. In fact, there is a very
high genetic correlation between educational attainment
and cognitive ability (R2 5 0.55 based on linkage
disequilibrium (LD) score regression) [22,73,74]. This
shared genetic background is probably the primary reason
for the high correlation between education and cognitive
ability [69,75]. Given the high genetic correlation, we
decided that adjusting for education as a covariate in the
model would lead to overadjustment and ultimately false-
negative findings in the study.
In conclusion, we discovered and replicated the relation
of 15 metabolites in blood to cognitive function in cogni-
tively healthy individuals. We found that six metabolites
S.J. van der Lee et al. / Alzheimer’s & Dementia 14 (2018) 707-722 719were associated with dementia and three with AD. The asso-
ciation of lifestyle factors to the metabolites associated with
cognitive ability and dementia opens new avenues for tar-
geted prevention.Acknowledgments
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1. Systematic review: Cognitive function is an impor-
tant indicator of brain health and a predictor of de-
mentia. Metabolomics could provide valuable new
insights into the determinants of cognitive function,
but, to date, studies of blood metabolite measures
and cognitive function are limited in size and find-
ings are rarely replicated.
2. Interpretation: We undertook a large study on the as-
sociations of circulating metabolites with general
cognitive ability and found a profile of 15 metabo-
lites to be consistently associated with general cogni-
tive ability, independently of high-density
lipoprotein cholesterol, low-density lipoprotein
cholesterol, triglycerides, glucose, and APOE geno-
types. Six of these metabolites were also associated
with risk of dementia. The metabolites in the profile
were associated with lifestyle factors.
3. Future directions: Future studies should examine the
molecular mechanisms underlying the observed as-
sociations between metabolites, cognitive function,
and dementia, whether metabolites can be used as
readouts for preventive or therapeutic interventions,
and whether selective interventions targeting metab-
olites would prevent dementia.
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